Zeftrax S Dosage/Direction for Use

May be administered intravenously or intramuscularly after reconstitution. Dosage in adults daily dose (in terms of Ceftriaxone) 1-2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infections. The total daily dose should not be exceeded 4 grams. Should be adjusted in patients with marked decreased renal function (creatine clearance of less than 30 mL/min) to compensate for the reduced clearance less than 15 mL/min should receive a maximum of 500 mg of Sulbactam every 12 hours (maximum dosage of 1 g of Sulbactam).
Pediatric patients for the treatment of skin and skin structure infections, the recommended total daily dose in terms of Ceftriaxone is 50 to 75 mg/kg given once a day (or in equally divided dose twice a day). The total daily doses should not be exceeded 1 gram.
For the treatment of acute bacterial otitis media, a single intramuscular dose (in terms of Ceftriaxone 50 mg/kg not exceeding 1 gram) is recommended.
For the treatment of serious miscellaneous infection other than meningitis, the recommended total daily dose (in terms of Ceftriaxone) is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose in terms of Ceftriaxone should not exceed 2 grams.
In the treatment of minorities, the recommended initial therapeutic dose (in terms of Ceftriaxone) may be 100 mg/kg (not exceeding 4 grams). The daily dose (in terms of Ceftriaxone) may be administered once a day (or equally divided by 12 hours). The usual duration of the therapy is 7 to 14 days. Generally, therapy should be continued for at least 2 days after the signs and symptoms even if infection has disappeared. The usual duration of therapy is 4 to 14 days in complicated infections, longer therapy may be required.
When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days. No dosage adjustment is necessary for patients with impairment of renal or hepatic function, however, blood levels should be monitored in patients with severe renal impairment (eg, dialysis patients) and in patients with both renal and hepatic dysfunctions.
Direction for Reconstitution: Dissolve dry powder to 10 mL of sterile water for injection. After adding sterile water for injection in the vial, agitate the vial until the powder dissolves completely in the solution. The reconstituted solution should be used immediately after preparation.
Single Use or Single Dose: Parenteral product should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.